All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for AMGEN, INC. · An American multinational biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 6

Budget/Appropriations

Policies impacting disease prevention.

Labor Issues/Antitrust/Workplace

Issues related to antitrust legislation.

Issues related to patent protections.

Health Issues

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.

Medicare/Medicaid

Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars.

Taxation/Internal Revenue Code

Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.